Sanofi ups the legal ante to block Lilly’s Lantus biosimilar

Damian Garde Sanofi has filed another lawsuit against Eli Lilly in hopes of beating back a biosimilar challenge for its top-selling insulin product, claiming its rival's in-development ...

Sanofi tiptoes toward selling some older products

Carly Helfand Back in April, Sanofi was said to be considering some spring cleaning, weighing a sale of older products to make room for the bolt-on deals CEO Chris Viehbacher wants ...

Sanofi CEO: No deals? No problem

Carly Helfand Pharma is riding an M&A deal wave like none the industry has ever seen, with companies looking to shed noncore businesses and bulk up in areas they want to focus on. ...

Reckitt may top Novartis, Sanofi in $12B race for Merck consumer unit

Tracy Staton With a final bid deadline looming, Merck & Co.'s consumer health unit still has several big-name pharma suitors. But Reckitt Benckiser, the Irish consumer specialist, ...

Sanofi CEO: Our pipeline is in the top 5

Damian Garde Despite the recent FDA rebuke of the blockbuster hopeful Lemtrada, Sanofi CEO Chris Viehbacher believes his company is poised to cash in on "a whole raft of new products" ...

Sanofi launches a new antibiotics effort, teams with Fraunhofer

John Carroll Sanofi is joining forces with researchers at Germany's Fraunhofer-Gesellschaft in the hunt for new antibiotics. The pharma giant is setting up a new collaboration that ...

Busy Regeneron busts Eylea sales forecasts, re-ups with Sanofi

Tracy Staton Yesterday, Regeneron CEO Len Schleifer announced that rather than the $ 377 million expected by analysts, Regeneron will report about $ 400 million in U.S. sales for macular ...

Sanofi is allowing open access from Jan. 1 on out

Carly Helfand Following in the footsteps of Big Pharma counterparts like GlaxoSmithKline, Sanofi says it will provide data, documents and reports on studies used to support U.S. and ...

FDA says nada to Lemtrada; will Sanofi be willing to invest in additional trials?

Eric Palmer Sanofi intends to appeal the FDA's denial of Lemtrada, its multiple sclerosis drug that was a key reason it paid $ 20.1 billion to buy Genzyme two years ago. But will ...

Sanofi and Regeneron Report Positive Results with Sarilumab

mia.burns Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial Sarilumab, Given Subcutaneously Every Other ...

Relax, PCSK9ers: FDA won’t roadblock blockbusters from Sanofi, Amgen

Damian Garde On the heels of new guidelines casting doubts on a much-hyped new class of cholesterol drugs, the FDA said it would not demand long and costly outcomes trials before approving ...

Sanofi gets mixed FDA blessing for MS drug Lemtrada

Damian Garde After a scathing staff review, Sanofi walked away from an FDA panel with mixed messages on its long-delayed multiple sclerosis drug, as agency advisers said the injection ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS